Maxinovel Pty., Ltd.

12 clinical trials · Sponsor

Record	Firm	Date
A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia (NCT07743112)	Maxinovel Pty., Ltd.	2025-09-05
A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors (NCT05425602)	Maxinovel Pty., Ltd.	2022-07-31
A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer (NCT05395780)	Maxinovel Pty., Ltd.	2022-06-01
A Study to Evaluate the Safety of MAX-40070 in Healthy Subjects (NCT05196711)	Maxinovel Pty., Ltd.	2022-02-28
A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer (NCT05130021)	Maxinovel Pty., Ltd.	2022-01-31
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) (NCT05061147)	Maxinovel Pty., Ltd.	2021-09-16
MAX-10181 in Patients With Advanced Solid Tumor (NCT05196360)	Maxinovel Pty., Ltd.	2021-08-11
MAX-10181 Given Orally to Patients With Advanced Solid Tumor (NCT04122339)	Maxinovel Pty., Ltd.	2020-02-11
MAX-40279-01 in Patients With Advanced Solid Tumors (NCT04183764)	Maxinovel Pty., Ltd.	2019-11-28
Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) (NCT04187495)	Maxinovel Pty., Ltd.	2019-04-16
MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) (NCT03412292)	Maxinovel Pty., Ltd.	2018-08-01

Track Maxinovel Pty., Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.